SOURCE-LINKED STUDY SUMMARY
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Abstract summarizedQuality not appraised
- What was studied
- Randomized trial comparing liraglutide with placebo alongside standard care, tracking cardiovascular death, nonfatal heart attack or stroke.
- Who / model studied
- 9340 people with type 2 diabetes and high cardiovascular risk; median follow-up was 3.8 years.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- The primary combined cardiovascular outcome occurred in 13.0% versus 14.9%. Cardiovascular deaths were 4.7% versus 6.0%. Individual nonfatal heart attacks, strokes and heart-failure admissions did not show statistically clear differences. Digestive problems were the most common reason for stopping liraglutide.
- Limitations & context
- Exploratory outcomes were tested without adjustment for making multiple comparisons.
Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1056/nejmoa1603827